Autoimmune Disease Clinical Trial
Working hypothesis and aims: Biotin is conjugated covalently to several proteins and use as
a co-factor. Conjugation of biotin to non-targeted, unspecific proteins (e.g.
immunoglobulins) leads to the breakage of the immune tolerance and to the formation of
anti-biotin antibodies. Anti-biotin antibodies will be found in correlation with the
progression and the present of autoimmune disease. In this research the correlation between
immune response against biotin and the formations of autoimmune disease, will be studied:
A. Assessment of the possibility that biotin elicit immune response involved in the
developmental stage of the autoimmune disease.
B. Assessment of the possibility that anti-biotin antibodies indicate the developmental
stage of the autoimmune disease and therefore can serve as an disease early stage marker.
Methods: A. Patient recruitment. Gathering participant's medical record and blood samples.
B. Records of clinical and biochemical measures. C. Serum of all patient will be tested for
the correlation between biotin level, biotin bound to antibodies and anti-biotin antibodies
to liver functions tests. D. Controlled test for repeatedly injected mice with biotinilated
self-antibodies. Level of anti-biotin will be tested and their influence on the mouse. E.
Determination of the correlation between biotinilated antibodies or anti-biotin antibodies
to disease eruption or severance and autoimmune disease.
Expected results :Serum biotin-protein levels and Anti biotin antibodies levels are
increased in patients with active autoimmune liver diseases.
Importance: The proof of connection between biotin-carrying immunoglobulins, anti biotin
antibodies and autoimmune diseases will open new research direction of possible factors that
cause to autoimmune disease.
Probable implications to Medicine: Identification of correlations between reaction to
biotine and autoimmune diseases will enable their usage as biomarkers for autoimmune
diseases, severity of the disease and personalization of treatment.
n/a
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01665196 -
18F-FDG PET/CT for IgG4-Related Disease
|
Early Phase 1 | |
| Withdrawn |
NCT02948855 -
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
|
||
| Completed |
NCT01815996 -
Identify Clinical Conditions That Increase Circulating DNA Levels
|
||
| Completed |
NCT02434458 -
Sudoscan in Patients With Autoimmune Disorders
|
N/A | |
| Completed |
NCT02263703 -
Immunogenicity of HPV Vaccine in Immunosuppressed Children
|
Phase 3 | |
| Completed |
NCT00013689 -
Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
|
Phase 1 | |
| Completed |
NCT00340600 -
Continuation of Follow-up of DES-Exposed Cohorts
|
||
| Not yet recruiting |
NCT05894707 -
Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 | |
| Active, not recruiting |
NCT00716066 -
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
|
Phase 2 | |
| Completed |
NCT00351377 -
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
|
Phase 3 | |
| Completed |
NCT00114530 -
Scleroderma: Cyclophosphamide or Transplantation
|
Phase 2/Phase 3 | |
| Completed |
NCT00001630 -
Treatment of Autoimmune Thrombocytopenia (AITP)
|
Phase 1 | |
| Completed |
NCT00372177 -
The Use of Anti-CD4 Monoclonal Antibody (mAb)-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis
|
Phase 1/Phase 2 | |
| Completed |
NCT00065390 -
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
|
Phase 1 | |
| Completed |
NCT00001658 -
Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections
|
Phase 4 | |
| Recruiting |
NCT03816345 -
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
|
Phase 1 | |
| Completed |
NCT00001306 -
Steroid Therapy in Autoimmune Premature Ovarian Failure
|
N/A | |
| Recruiting |
NCT03715699 -
Leflunomide Treatment for IgG4-RD
|
N/A | |
| Completed |
NCT02925351 -
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
|
Early Phase 1 |